Lyell Immunopharma, Inc.
LYL273
metastatic colorectal cancer (mCRC)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on LYL273 for metastatic colorectal cancer (mCRC) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 12h ago
“the FDA granted LYL273 Fast Track designation for the treatment of mCRC.”